ÀڱðæºÎ¾Ï ¼±º°°ËÁø¿¡ À־ º´ÇÕ°ËÁø[¼¼Æ÷Áø(ThinPrep(R)), HPV DNA test (Hybrid capture(R) 2), ÀڱðæºÎÈ®´ë ÃÔ¿µ¼ú]ÀÇ ºñ±³Æò°¡
The comparative evaluation of clinical screening in combined tests [cytology (ThinPrep(R)), HPV DNA test (Hybrid capture(R) 2), cervicography] for uterine cervical cancer

Journal of Gynecologic Oncology 2007³â 18±Ç 1È£ p.17 ~ p.25

¾ÈűÔ(Ahn Tae-Gyu) - Á¶¼±´ëÇб³ ÀÇ°ú´ëÇÐ »êºÎÀΰúÇб³½Ç
¹ÚÁؼ±(Park Jun-Sun) - Á¶¼±´ëÇб³ ÀÇ°ú´ëÇÐ »êºÎÀΰúÇб³½Ç
ÇѼ¼ÁØ(Han Sei-Jun) - Á¶¼±´ëÇб³ ÀÇ°ú´ëÇÐ »êºÎÀΰúÇб³½Ç

Abstract

Objective: Since the accuracy of Pap smear for cervical neoplasm has been questioned, a number of adjunctive tests have been developed. The purpose of this study was to evaluate which protocol is the most effective screening test among cervical cytology (ThinPrep(R)), HPV DNA test (Hybrid capture(R) II) and cervicography.

Methods: We chose 252 patients who were underwent the biopsy among 829 patients who visited our hospital for cervical cancer screening test. These 252 patients were engaged in this study simultaneously. They underwent triple combined test [cervical cytology (ThinPrep(R)), HPV DNA test (Hybrid capture(R) III, cervicography] and colposcopic-directed biopsy or biopsy on operation for diagnostic evaluation.

Results: The triple combined test showed a sensitivity of 96.0%, while double combined test [cervical cytology (ThinPrep(R))+cervicography] showed a sensitivity of 89.0%, the other double combined test [cervical cytology (ThinPrep(G))+HPV DNA test (Hybrid capture(R) III] showed a sensitivity of 86.7%. Cervicography showed a specificity of 75.4% (highest among the single test), positive predictability of 89.8% (also highest).

Conclusion: The sensitivity of cervical cytology was markedly improved by combination with HPV DNA test and cervicography. So the triple combined tests which improved the high false negative rate of cervical cytology may be a new effective method as a cervical cancer screening test, if the effectiveness could be confirmed by mass screening study.

Å°¿öµå

ÀڱðæºÎ¾Ï, ¼¼Æ÷Áø °Ë»ç(ThinPrep(R)), HPV DNA test (Hybrid capture(R) 2), ÀڱðæºÎÈ®´ë ÃÔ¿µ¼ú
Cervical cancer, Cervical cytology (ThinPrep(R)), HPV DNA test (Hybrid capture(R) 2), Cervicography
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
SCI(E) MEDLINE ÇмúÁøÈïÀç´Ü(KCI) KoreaMed ´ëÇÑÀÇÇÐȸ ȸ¿ø 
ÁÖÁ¦ÄÚµå
ÁÖÁ¦¸í(Target field)
¿¬±¸´ë»ó(Population)
¿¬±¸Âü¿©(Sample size)
´ë»ó¼ºº°(Gender)
Áúº´Æ¯¼º(Condition Category)
¿¬±¸È¯°æ(Setting)
¿¬±¸¼³°è(Study Design)
¿¬±¸±â°£(Period)
ÁßÀç¹æ¹ý(Intervention Type)
ÁßÀç¸íĪ(Intervention Name)
Å°¿öµå(Keyword)
À¯È¿¼º°á°ú(Recomendation)
The sensitivity of cervical cytology was markedly improved by combination with HPV DNA test and cervicography.
¿¬±¸ºñÁö¿ø(Fund Source)
±Ù°Å¼öÁØÆò°¡(Evidence Hierarchy)
ÃâÆdz⵵(Year)
Âü¿©ÀúÀÚ¼ö(Authors)
´ëÇ¥ÀúÀÚ
KCDÄÚµå
ICD 03
°Ç°­º¸ÇèÄÚµå